Anti-VWF (Caplacizumab), Humanized Antibody

Anti-VWF (Caplacizumab), Humanized Antibodyis available at Gentaur for Next week Delivery.

Description: The research-grade biosimilar is a humanized monoclonal antibody fragment that targets the von Willebrand factor (VWF). The original monoclonal antibody is a bivalent single-variable-domain linked by a three alanine linker. The antibody was approved for the treatment of acquired thrombotic thrombocytopenic purpura (TTP). Acquired TTP occurs due to the production of inhibitory autoantibodies against ADAMTS13. This leads to decreased ADAMTS13 activity that prevents cleavage of the von Willebrand factor. As a result, ultra-large von Willebrand factor multimers form that results in binding of the A1 domains of the VWF multimers to the platelets via glycoprotein Ibα and cause platelet aggregation. Aggregation of platelets leads to the formation of microthrombi, which causes ischemia of the tissues and dysfunction of multiple organs, ultimately leading to cognitive deficits, arterial hypertension, and early death. The original monoclonal antibody binds to the A1 domains of the VWF and inhibits the association with platelets thus preventing platelet aggregation and microthrombi formation

Immunogen Sequence:Human VWF

Target Alternative Name:VWD, F8VWF, VWF, von Willebrand factor, Coagulation Factor VIII VWF

Species Reactivities:Human

Tag Line:The biosimilar is a humanized monoclonal antibody that targets von Willebrand factor (VWF)

Formulation:In PBS, pH 7.5

Purification: Protein A purified

Application:/

Positive Control:/

Application And Usages:/

Handling:The antibody solution should be gently mixed before use.